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submandibular triangle (p < 0.0001). In 69% of patients (n = 11), 
the dose to the transferred submandibular gland was below the 
QUANTEC dose constraint of mean < 35 Gy. Four of the remaining 
patients had pathologic involvement of the contralateral level I 
nodes and could not have the transferred gland spared, while 
one patient had a large pT4 lip lesion and coverage of the tumour 
bed resulted in a dose of 36.0 Gy to the transferred gland. 
Conclusions: The mSGT technique significantly reduced the dose 
to the submandibular gland from a median dose very likely to 
produce xerostomia to a dose below accepted dose constraints. 
Adoption of this technique may reduce the rate of xerostomia 
and improve quality of life in patients with oral cavity cancer 
undergoing adjuvant RT. 
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Purpose: Urothelial carcinoma-associated 1 (UCA1) is a recently 
identified long non-coding RNA which plays an oncologic role in 
several cancers and enhances cellular proliferation, invasion, 
and tumour growth. It is upregulated in prostate tumours, but its 
involvement in therapy response has not been investigated. 
Methods and Materials: To simulate the clinical scenario of 
ionizing-radiation resistance (IRR), we created IRR PCa cell lines 
by treatment with mock irradiation (parental cells) or IR 
(conventional fractionation (CF): 2 Gy daily X 59 for DU145-CF-
IRR cells). We performed gene array profiling to discover 
dysregulated genes in DU145-CF-IRR cells and identified UCA1. 
We investigated the mechanism of UCA1 on aggression and 
response to radiation and chemotherapy by performing miRNA 
comparative profiling (NanoString platform), Proteome Profiler 
Array, proliferation assays, soft agar colony formation, 
clonogenic assays, invasion assay, γ-H2AX assay, cell cycle 
profiling, MTS assay and western blotting. We also studied the 
clinical significance of UCA1 expression in two cohorts of PCa 
patients; CPC-GENE (n = 210; patients with intermediate-risk 
PCa) and MSKCC (n = 131; PCa patients treated with radical 
prostatectomy).  
Results: DU145-CF-IRR cells were radioresistant and acquired an 
aggressive phenotype. We found that UCA1 expression was 
significantly higher in DU145-CF-IRR compared to parental cells 
using gene array profiling and confirmatory qRT-PCR analysis 
(170-fold). Interestingly, UCA1 siRNA-knockdown reversed the 
aggressive phenotype and significantly increased sensitivity to IR 
and docetaxel. We demonstrated that UCA1 depletion inhibited 
growth, induced cell cycle arrest at the G2/M transition and 
decreased activation of the pro-survival Akt pathway. 
Furthermore, we found that UCA1 overexpression was associated 
with a trend toward lower biochemical recurrence-free survival 
in CPC-GENE patients (HR = 1.4, p = 0.28) and its aberrant 
expression was significantly associated with decreased five-year 
disease-free survival in publically available MSKCC database 
(84.5% versus 52%; HR = 2.19, log-rank test p = 0.005).  
Conclusions: We showed for the first time that UCA1 can 
influence cancer aggression, radiation and chemotherapy 
response in PCa, which may occur through altered Akt signaling. 
Our results also suggest that UCA1 can have prognostic value in 
PCa. Future work will investigate UCA1 as a therapeutic target 
and prognostic biomarker for PCa.  
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Purpose: Pain is experienced by 50%-75% of patients with bone 
metastases, representing a major source of morbidity amongst 
cancer patients. Magnetic Resonance- Guided High Intensity 
Focused Ultrasound (MRgHIFU) is a new, non-invasive, outpatient 
treatment modality for painful bone metastases. The aim of this 
study is to analyze urinary cytokines/chemokines pattern after 
MRgHIFU for palliative treatment of painful bone metastases. 
The findings will be compared to the cytokines/chemokines 
pattern post single 8 Gy fraction radiation from our previous 
study.  
Methods and Materials: Urine samples were collected from 
patients with painful bone metastases three days before and two 
days after treatment with MRgHIFU. Each urine sample was 
tested for pro-inflammatory cytokines and anti-inflammatory 
cytokines. Patients received teaching on how to collect urine 
samples on their own. The Millipore Milliplex 42-Plex Cyto-
kine/Chemokine Kit™ was used to measure urinary levels of a 
panel of cytokines/chemokines.  
Results: Ten patients were enrolled for the study and provided 
urine samples three days before and two days after treatment 
with MRgHIFU. The following fifteen cytokines were above the 
level of detection (LOD) in at least 50% of patients at both pre-
MRgHIFU and post-MRgHIFU: EGF, Eotaxin, Fit-3 Ligand, 
Fractalkine, G-CSF, GRO, IFN-alpha2, IL-1ra, IL-8, IP-10, MCP-1, 
PDGF-AA, RANTES, sIL-2Ra, and VEGF. Nine urinary cytokines 
significantly decreased post MRgHIFU, namely, Eotaxin, GRO, IL-
8, IL-13, IP-10, MCP-1, MIP-1beta, RANTES, and sIL_2Ra. In 
addition, there were significant differences between post 
MRgHIFU and post-8 Gy fraction radiation in most urinary 
cytokines. 
Conclusions: Nine urinary cytokines significantly decreased post 
MRgHIFU which correlated with pain response in patients with 
painful bone metastases. 
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Purpose: Radiation fibrosis (RF) is a side effect of radiotherapy 
characterized by irreversible scarring of normal tissue resulting 
in functional morbidity and decreased quality of life. Adipose-
derived stromal cells (ADSCs) have been shown to regulate the 
metabolic profile of target tissue through the secretion of 
cytokines and growth factors. We hypothesize that ADSCs may be 
therapeutically effective for RF through metabolic 
reprogramming and that these ADSC-mediated metabolic 
alterations can be utilized to identify novel drugs for the 
treatment of RF.  
Method: An RF model was created by radiating the hind limb of 
C3H mice. This model showed a dose dependent leg contracture 
and histological findings of fibrosis. Primary cultured ADSCs 
derived from C3H mice were identified based on 
immunophenotyping and their differentiation potential down the 
mesenchymal lineage. 
Results: ADSC transplantation was shown to be therapeutically 
effective for RF based on an improvement in leg contracture (p 
< 0.05) and reduced collagen deposition (p < 0.01). Whole 
transcriptome over-representation and gene set enrichment 
pathway analysis revealed that lipid metabolism and glycolysis 
were two pathways strongly dysregulated in RF and were 
reversed with ADSC treatment. To identify novel drugs to be 
repurposed for the treatment of RF, ADSC-mediated 
transcriptome alterations were compared with drug-mediated 
transcriptome alterations in CMAP, a pharmacogenomics 
CARO 2016                                                                                                                                                                  S11 
_________________________________________________________________________________________________________ 
database. Twenty-two FDA-approved candidate drugs shifted the 
transcriptome similarly to ADSC treatment; and are thereby 
promising for RF treatment. Drug screening revealed that 
candidates which upregulate lipid metabolism or 
gluconeogenesis decreased collagen production and/or secretion 
by TGF-B stimulated fibroblasts.  
Conclusions: ADSC transplantation may be an effective 
treatment for the reversal of RF via metabolic reprogramming. 
Through pharmacogenomics analysis, we identified FDA 
approved drugs with potential to be repurposed for the 
treatment of RF based on their potential to induce metabolic 
alterations similar to ADSCs. Our data highlights the importance 
of metabolic dysregulation in the pathogenesis of RF and the 
importance of targeting these pathways in reversing RF. 
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Purpose: The mutational landscape of anal cancers has not been 
well studied. The purpose of this study was to perform the first 
analysis characterizing the types and frequencies of mutations in 
anal cancers from patients treated with radical 
chemoradiotherapy (CRT) using comprehensive next-generation 
sequencing (NGS). 
Methods and Materials: Pre-treatment formalin-fixed, paraffin-
embedded anal cancer specimens from 30 patients treated with 
radical CRT for anal cancer at a single tertiary institution were 
evaluated. Ninety percent of cases were squamous cell cancers. 
M:F ratio was 1:2.3; median patient age was 56 years (range: 34-
80): 47% (n = 14) had T2 disease. Tumour DNA was extracted and 
assayed for 50 oncogenes and tumour suppressor genes using the 
Ampliseq Cancer Hot Spot Panel (CHPv2) on the Ion PGM using a 
316v2 chip. Mean depth of target coverage was 1005X. 
Bioinformatic analysis was performed using Torrent Suite 
Software version 5.03. Variants from reference hg19 were called 
using variant Caller plugin 5.03.5 and annotated with Ion 
Reporter Software 5.0. All variants were manually reviewed 
using Broad Institute’s Integrative Genomics Viewer. Mutational 
status was determined and associated with HPV status. 
Results: Twenty-five of 30 cases (83%) were evaluable for full 
mutational analysis. The most common mutation identified was 
PIK3CA (4/25 of cases, 16%); 75% (3/4) were in exon 9. Overall, 
Pi3K/AKT/mTOR pathway activating mutations were seen in 24% 
(6/25 of cases). Other mutations were very rare: FBXW7 (n = 1, 
4%), p53 (n = 1, 4%), IDH1 (n = 1, 4%). One tumour had NRAS 
mutation; notably all other MAPK pathway genes were wild-type. 
Twenty-one of 25 cases were HPV sub-typed; 90% (19/21) were 
positive for high-risk HPV. Only p53 mutation was associated with 
HPV negative status. 
Conclusions: Pi3K/AKT/mTOR activating mutations were the 
most frequently observed in patients with anal cancer treated 
with CRT. Anal cancers have targetable mutations, making them 
amenable for consideration of therapeutics such as Pi3K and 
EGFR inhibitors. Validation with a larger data set will be 
undertaken to confirm these findings, and to determine their 
association with clinical outcome parameters. 
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Purpose: The immune microenvironment within tumours is 
critical to oncogenesis, cancer progression, and radiotherapy 
(RT) efficacy. Immunohistochemistry (IHC) is a convenient and 
inexpensive method by which to characterize the immune 
infiltrates in pathology samples. However, manually reading 
multiple IHC stains on tissue microarrays (TMA) is labor intensive 
and subject to bias. Our objective is to apply computer image 
analysis tools to localize and quantify immune markers in oral 
cavity squamous cell carcinoma (OCSCC) samples and determine 
their prognostic implications. 
Methods and Materials: A 91-patient OCSCC TMA was stained for 
the markers: CD3, CD4, CD8, FOXP3, IDO, and PD-L1. Tissue 
Studio (Definiens AG, Munich, Germany) was used to enumerate 
the number of marker-positive cells and to quantify the staining 
intensity for IDO and PD-L1. Cell populations were assigned to 
stromal or epithelial (tumour) compartments according to a mask 
derived from a pan-cytokeratin stain using a custom Matlab 
script. Automated methods were validated against manual tissue 
segmentation, cell count and stain intensity quantification. 
Univariate associations of cell counts and stain intensities with 
smoking status, TNM stage, overall survival (OS), and disease-
free survival (DFS) were determined. 
Results: 80.6% (737/910) of TMA cores were suitable for analysis, 
39.8% (35/88) of patients had a known never-smoker history, and 
34.1% (31/91) of patients were treated with RT. Comparison of 
automated to manual tissue segmentation showed good 
agreement (Kappa coefficient range: 0.61- 0.75). Automated and 
manual cell counts and stain intensities were highly correlated 
(Pearson correlation coefficient range: 0.46 - 0.91, p < 0.001 for 
all). Individual cell counts and stain intensities within the 
stromal, epithelial, or combined compartments did not display 
significant association with stage, OS or DFS in the set of all 
patients and in the subset of patients who received RT (p ≥ 0.05). 
Compared to never-smokers, current and ex-smokers had an 
increased density of FOXP3 cells in the epithelial compartment 
(OR 12.49, p = 0.06), and stronger PD-L1 stain intensity in both 
epithelial and stromal compartments (OR 4.54, p = 0.08; OR 6.58, 
p = 0.05); these results were confirmed by manual scores. 
Conclusions: Computer-assisted image analysis can be used for 
robust quantification of cellular populations by IHC. Our 
automated methods show that current and ex-smokers have 
higher density of FOXP3 cells in the epithelial compartment and 
have more intense PD-L1 staining in both epithelial and stromal 
compartments. This result is validated with manual IHC scoring. 
This proof-of-principle study demonstrates the utility of 
computer-assisted image analysis for high-throughput 
assessment of multiple IHC markers on TMAs, with potential 
implications for studies on prognostic and predictive biomarkers.  
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Purpose: Early studies have suggested a correlation between 
fluorodeoxyglucose-positron emission tomography (FDG-PET) 
uptake and epidermal growth factor receptor (EGFR) mutation 
status in patients with non-small cell lung cancer (NSCLC). 
Results from these few studies are conflicting and limited by 
small subject numbers. The purpose of this study was to 
determine if such a correlation exists in a large population using 
standardized diagnostic protocols. 
Methods and Materials: A retrospective review was conducted 
of patients with metastatic non-squamous, non-neuroendocrine, 
NSCLC who had EGFR mutation testing and FDG-PET imaging 
between March 2010 and March 2012. All patients had FDG-PET 
imaging at a central facility using the same scanning protocol. 
Data was collected on the maximum standardized uptake value 
(SUVmax) of the primary lung tumour. EGFR mutation testing was 
done at a central lab using a rapid polymerase chain reaction-
based detection technique. Patients were divided into EGFR 
mutation positive (EGFR+) and EGFR wild type (WT) cohorts. 
